2026-09-20T18:09:00Zhttps://dspace.mit.edu/server/oai/request

oai:dspace.mit.edu:1721.1/781582026-06-06T01:05:17Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023

Fiona Murray and Anthony Sinskey. Campbell, Elyssa Sarah Harvard--MIT Program in Health Sciences and Technology. Harvard University--MIT Division of Health Sciences and Technology 2013-03-28T18:09:20Z 2013-03-28T18:09:20Z 2012 http://hdl.handle.net/1721.1/78158 829680663 Thesis (S.M. in Health Sciences and Technology)--Harvard-MIT Program in Health Sciences and Technology, 2012. "September 2012." Cataloged from PDF version of thesis. Includes bibliographical references (p. 37-40). Successful translation of scientific discovery into new medicines is most successful with collaboration between academics - scientists and physicians - and industry. In recent years, there has been increasing concern at academic medical centers about the impact of relationships with industry on patient care and student education. This has generally resulted in more stringent conflict-of-interest rules. This paper seeks to better understand the impact of these conflict-of-interest rules. In the first part, it explores research to-date on the importance of relationships between industry and academia and discusses some of the concerns that have arisen. In the second part, this relationship is better characterized with clinical trial data. The findings suggest that there is a strong trend towards schools with higher conflict-of-interest rules having fewer clinical trials. This suggests that although there may be benefits to stricter regulation, there are trade-offs in terms of clinical translation. by Elyssa Sarah Campbell. S.M. in Health Sciences and Technology 50 p. eng Massachusetts Institute of Technology M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. http://dspace.mit.edu/handle/1721.1/7582 Harvard--MIT Program in Health Sciences and Technology. From bench to bedside : impact of conflict-of-interest restrictions at academic medical centers on clinical trials Impact of conflict-of-interest restrictions at academic medical centers on clinical trials Thesis application/pdf false Publication unknown unknown <Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="7ed17816-a65d-42a8-8da6-a13948921168"> <Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type> <Language>eng</Language> <Title>From bench to bedside : impact of conflict-of-interest restrictions at academic medical centers on clinical trials</Title> <Subtitle>Impact of conflict-of-interest restrictions at academic medical centers on clinical trials</Subtitle> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2012</PublicationDate> <Authors> <Author> <DisplayName>Campbell, Elyssa Sarah</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <DisplayName>Massachusetts Institute of Technology</DisplayName> <OrgUnit /> </Publisher> </Publishers> <License>http://dspace.mit.edu/handle/1721.1/7582</License> <Keyword>Harvard--MIT Program in Health Sciences and Technology.</Keyword> <Abstract>Successful translation of scientific discovery into new medicines is most successful with collaboration between academics - scientists and physicians - and industry. In recent years, there has been increasing concern at academic medical centers about the impact of relationships with industry on patient care and student education. This has generally resulted in more stringent conflict-of-interest rules. This paper seeks to better understand the impact of these conflict-of-interest rules. In the first part, it explores research to-date on the importance of relationships between industry and academia and discusses some of the concerns that have arisen. In the second part, this relationship is better characterized with clinical trial data. The findings suggest that there is a strong trend towards schools with higher conflict-of-interest rules having fewer clinical trials. This suggests that although there may be benefits to stricter regulation, there are trade-offs in terms of clinical translation.</Abstract> <Access xmlns="http://purl.org/coar/access_right" > </Access> </Publication>